Search

Your search keyword '"Schaap, Jeroen"' showing total 119 results
Start Over Author "Schaap, Jeroen" Search Limiters Full Text
119 results on '"Schaap, Jeroen"'

2. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Author

Joseph, Richard W, Elassaiss-Schaap, Jeroen, Kefford, Richard, Hwu, Wen-Jen, Wolchok, Jedd D, Joshua, Anthony M, Ribas, Antoni, Hodi, F Stephen, Hamid, Omid, Robert, Caroline, Daud, Adil, Dronca, Roxana, Hersey, Peter, Weber, Jeffrey S, Patnaik, Amita, de Alwis, Dinesh P, Perrone, Andrea, Zhang, Jin, Kang, S Peter, Ebbinghaus, Scot, Anderson, Keaven M, and Gangadhar, Tara C

Subjects
Cancer, Clinical Research, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827).Experimental Design: BTS was quantified by adding the sum of the longest dimensions of all measurable baseline target lesions. BTS as a dichotomous and continuous variable was evaluated with other baseline factors using logistic regression for objective response rate (ORR) and Cox regression for overall survival (OS). Nominal P values with no multiplicity adjustment describe the strength of observed associations.Results: Per central review by RECIST v1.1, 583 of 655 patients had baseline measurable disease and were included in this post hoc analysis. Median BTS was 10.2 cm (range, 1-89.5). Larger median BTS was associated with Eastern Cooperative Oncology Group performance status 1, elevated lactate dehydrogenase (LDH), stage M1c disease, and liver metastases (with or without any other sites; all P ≤ 0.001). In univariate analyses, BTS below the median was associated with higher ORR (44% vs. 23%; P < 0.001) and improved OS (HR, 0.38; P < 0.001). In multivariate analyses, BTS below the median remained an independent prognostic marker of OS (P < 0.001) but not ORR. In 459 patients with available tumor programmed death ligand 1 (PD-L1) expression, BTS below the median and PD-L1-positive tumors were independently associated with higher ORR and longer OS.Conclusions: BTS is associated with many other baseline clinical factors but is also independently prognostic of survival in pembrolizumab-treated patients with advanced melanoma. Clin Cancer Res; 24(20); 4960-7. ©2018 AACR See related commentary by Warner and Postow, p. 4915.

Published
2018

3. Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study

Author

Malgie, Jishnu, primary, Wilde, Mariëlle I., additional, Clephas, Pascal R.D., additional, Emans, Mireille E., additional, Koudstaal, Stefan, additional, Schaap, Jeroen, additional, Mosterd, Arend, additional, van Ramshorst, Jan, additional, Wardeh, Alexander J., additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, Wierda, Eric, additional, Borleffs, C. Jan Willem, additional, Saraber, Colette, additional, Beeres, Saskia L.M.A., additional, van Kimmenade, Roland, additional, Jansen Klomp, Wouter, additional, Denham, Robert, additional, da Fonseca, Carlos A., additional, Klip, IJsbrand T., additional, Manintveld, Olivier C., additional, van der Boon, Robert M.A., additional, van Ofwegen, Clara E.E., additional, Yilmaz, Ayten, additional, Pisters, Ron, additional, Linssen, Gerard C.M., additional, Faber, Nikola, additional, van Heerebeek, Loek, additional, van de Swaluw, Julio E.C., additional, Bouhuijzen, Lex J., additional, Post, Marco C., additional, Kuijper, Aaf F.M., additional, Wu, Ka wai, additional, van Beek, Eugène A., additional, Hesselink, Tim, additional, Kleijn, Lennaert, additional, Kurvers, Maurice J.M., additional, Tio, René A., additional, Langerveld, Jorina, additional, van Dalen, Bas M., additional, van Eck, J.W. Martijn, additional, Handoko, M. Louis, additional, Hermans, Walter R.M., additional, Koornstra‐Wortel, Hetty J.J., additional, Szymanski, Mariusz K., additional, Rooker, Dennis, additional, Tandjung, Kenneth, additional, Eijsbouts, Sabine C.M., additional, Asselbergs, Folkert W., additional, van der Meer, Peter, additional, Brunner‐La Rocca, Hans‐Peter, additional, de Boer, Rudolf A., additional, and Brugts, Jasper J., additional

Published
2024
Full Text
View/download PDF

4. RELEASE-HF study:a protocol for an observational, registry-based study on the effectiveness of telemedicine in heart failure in the Netherlands

Author

van Eijk, Jorna, Luijken, Kim, Jaarsma, Tiny, Reitsma, Johannes B., Schuit, Ewoud, Frederix, Geert W.J., Derks, Lineke, Schaap, Jeroen, Rutten, Frans H., Brugts, Jasper, de Boer, Rudolf A., Asselbergs, Folkert W., Trappenburg, Jaap C.A., van Eijk, Jorna, Luijken, Kim, Jaarsma, Tiny, Reitsma, Johannes B., Schuit, Ewoud, Frederix, Geert W.J., Derks, Lineke, Schaap, Jeroen, Rutten, Frans H., Brugts, Jasper, de Boer, Rudolf A., Asselbergs, Folkert W., and Trappenburg, Jaap C.A.

Abstract

Introduction:Meta-analyses show postive effects of telemedicine in heart failure (HF) management on hospitalisation, mortality and costs. However, these effects are heterogeneous due to variation in the included HF population, the telemedicine components and the quality of the comparator usual care. Still, telemedicine is gaining acceptance in HF management. The current nationwide study aims to identify (1) in which subgroup(s) of patients with HF telemedicine is (cost-)effective and (2) which components of telemedicine are most (cost-) effective. Methods and analysis:The RELEASE-HF ('REsponsible roLl-out of E-heAlth through Systematic Evaluation -Heart Failure') study is a multicentre, observational, registry-based cohort study that plans to enrol 6480 patients with HF using data from the HF registry facilitated by the Netherlands Heart Registration. Collected data include patient characteristics, treatment information and clinical outcomes, and are measured at HF diagnosis and at 6 and 12 months afterwards. The components of telemedicine are described at the hospital level based on closed-ended interviews with clinicians and at the patient level based on additional data extracted from electronic health records and telemedicine-generated data. The costs of telemedicine are calculated using registration data and interviews with clinicians and finance department staff. To overcome missing data, additional national databases will be linked to the HF registry if feasible. Heterogeneity of the effects of offering telemedicine compared with not offering on days alive without unplanned hospitalisations in 1 year is assessed across predefined patient characteristics using exploratory stratified analyses. The effects of telemedicine components are assessed by fitting separate models for component contrasts. Ethics and dissemination:The study has been approved by the Medical Ethics Committee 2021 of the University Me

Published
2024

5. Guideline implementation, drug sequencing, and quality of care in heart failure:design and rationale of TITRATE-HF

Author

Clephas, Pascal R.D., Malgie, Jishnu, Schaap, Jeroen, Koudstaal, Stefan, Emans, Mireille, Linssen, Gerard C.M., de Boer, Grytsje A., van Heerebeek, Loek, Borleffs, C. Jan Willem, Manintveld, Olivier C., van Empel, Vanessa, van Wijk, Sandra, van den Heuvel, Mieke, da Fonseca, Carlos, Damman, Kevin, van Ramshorst, Jan, van Kimmenade, Roland, van de Ven, Arjen R.T., Tio, René A., van Veghel, Dennis, Asselbergs, Folkert W., de Boer, Rudolf A., van der Meer, Peter, Greene, Stephen J., Brunner-La Rocca, Hans Peter, Brugts, Jasper J., Clephas, Pascal R.D., Malgie, Jishnu, Schaap, Jeroen, Koudstaal, Stefan, Emans, Mireille, Linssen, Gerard C.M., de Boer, Grytsje A., van Heerebeek, Loek, Borleffs, C. Jan Willem, Manintveld, Olivier C., van Empel, Vanessa, van Wijk, Sandra, van den Heuvel, Mieke, da Fonseca, Carlos, Damman, Kevin, van Ramshorst, Jan, van Kimmenade, Roland, van de Ven, Arjen R.T., Tio, René A., van Veghel, Dennis, Asselbergs, Folkert W., de Boer, Rudolf A., van der Meer, Peter, Greene, Stephen J., Brunner-La Rocca, Hans Peter, and Brugts, Jasper J.

Abstract

Aims: Current heart failure (HF) guidelines recommend to prescribe four drug classes in patients with HF with reduced ejection fraction (HFrEF). A clear challenge exists to adequately implement guideline-directed medical therapy (GDMT) regarding the sequencing of drugs and timely reaching target dose. It is largely unknown how the paradigm shift from a serial and sequential approach for drug therapy to early parallel application of the four drug classes will be executed in daily clinical practice, as well as the reason clinicians may not adhere to new guidelines. We present the design and rationale for the real-world TITRATE-HF study, which aims to assess sequencing strategies for GDMT initiation, dose titration patterns (order and speed), intolerance for GDMT, barriers for implementation, and long-term outcomes in patients with de novo, chronic, and worsening HF. Methods and results: A total of 4000 patients with HFrEF, HF with mildly reduced ejection fraction, and HF with improved ejection fraction will be enrolled in >40 Dutch centres with a follow-up of at least 3 years. Data collection will include demographics, physical examination and vital parameters, electrocardiogram, laboratory measurements, echocardiogram, medication, and quality of life. Detailed information on titration steps will be collected for the four GDMT drug classes. Information will include date, primary reason for change, and potential intolerances. The primary clinical endpoints are HF-related hospitalizations, HF-related urgent visits with a need for intravenous diuretics, all-cause mortality, and cardiovascular mortality. Conclusions: TITRATE-HF is a real-world multicentre longitudinal registry that will provide unique information on contemporary GDMT implementation, sequencing strategies (order and speed), and prognosis in de novo, worsening, and chronic HF patients.

Published
2024

6. Embedding routine health care data in clinical trials:with great power comes great responsibility

Author

Handoko, M. Louis, de Man, Frances S., Brugts, Jasper J., van der Meer, Peter, Rhodius-Meester, Hanneke F.M., Schaap, Jeroen, van de Kamp, H. J.Rik, Houterman, Saskia, van Veghel, Dennis, Uijl, Alicia, Asselbergs, Folkert W., Handoko, M. Louis, de Man, Frances S., Brugts, Jasper J., van der Meer, Peter, Rhodius-Meester, Hanneke F.M., Schaap, Jeroen, van de Kamp, H. J.Rik, Houterman, Saskia, van Veghel, Dennis, Uijl, Alicia, and Asselbergs, Folkert W.

Abstract

Randomised clinical trials (RCTs) are vital for medical progress. Unfortunately, ‘traditional’ RCTs are expensive and inherently slow. Moreover, their generalisability has been questioned. There is considerable overlap in routine health care data (RHCD) and trial-specific data. Therefore, integration of RHCD in an RCT has great potential, as it would reduce the effort and costs required to collect data, thereby overcoming some of the major downsides of a traditional RCT. However, use of RHCD comes with other challenges, such as privacy issues, as well as technical and practical barriers. Here, we give a current overview of related initiatives on national cardiovascular registries (Netherlands Heart Registration, Heart4Data), showcasing the interrelationships between and the relevance of the different registries for the practicing physician. We then discuss the benefits and limitations of RHCD use in the setting of a pragmatic RCT from a cardiovascular perspective, illustrated by a case study in heart failure.

Published
2024

7. The different risk of new-onset, chronic, worsening, and advanced heart failure:A systematic review and meta-regression analysis

Author

Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., Brugts, Jasper J., Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., and Brugts, Jasper J.

Abstract

Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all-cause mortality and HF hospitalizations associated with new-onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF. Methods and results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30-day and 1-year all-cause mortality, as well as 1-year HF hospitalization. Studies were pooled using random effects meta-analysis, and mixed-effects meta-regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30-day mortality rates did not reveal a significant distinction between hospital-admitted patients, with rates of 10.13% for new-onset HF and 8.11% for WHF (p = 0.10). However, the 1-year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new-onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend. Conclusions: Our meta-analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF.

Published
2024

8. Embedding routine health care data in clinical trials: with great power comes great responsibility

Author

Cardiometabolic Health, Handoko, M Louis, de Man, Frances S, Brugts, Jasper J, van der Meer, Peter, Rhodius-Meester, Hanneke F M, Schaap, Jeroen, van de Kamp, H J Rik, Houterman, Saskia, van Veghel, Dennis, Uijl, Alicia, Asselbergs, Folkert W, Cardiometabolic Health, Handoko, M Louis, de Man, Frances S, Brugts, Jasper J, van der Meer, Peter, Rhodius-Meester, Hanneke F M, Schaap, Jeroen, van de Kamp, H J Rik, Houterman, Saskia, van Veghel, Dennis, Uijl, Alicia, and Asselbergs, Folkert W

Published
2024

9. RELEASE-HF study: a protocol for an observational, registry-based study on the effectiveness of telemedicine in heart failure in the Netherlands

Author

van Eijk, Jorna, primary, Luijken, Kim, additional, Jaarsma, Tiny, additional, Reitsma, Johannes B, additional, Schuit, Ewoud, additional, Frederix, Geert W J, additional, Derks, Lineke, additional, Schaap, Jeroen, additional, Rutten, Frans H, additional, Brugts, Jasper, additional, de Boer, Rudolf A, additional, Asselbergs, Folkert W, additional, and Trappenburg, Jaap C A, additional

Published
2024
Full Text
View/download PDF

10. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE‐HF

Author

Clephas, Pascal R. D., primary, Malgie, Jishnu, additional, Schaap, Jeroen, additional, Koudstaal, Stefan, additional, Emans, Mireille, additional, Linssen, Gerard C. M., additional, de Boer, Grytsje A., additional, van Heerebeek, Loek, additional, Borleffs, C. Jan Willem, additional, Manintveld, Olivier C., additional, van Empel, Vanessa, additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, da Fonseca, Carlos, additional, Damman, Kevin, additional, van Ramshorst, Jan, additional, van Kimmenade, Roland, additional, van de Ven, Arjen R. T., additional, Tio, René A., additional, van Veghel, Dennis, additional, Asselbergs, Folkert W., additional, de Boer, Rudolf A., additional, van der Meer, Peter, additional, Greene, Stephen J., additional, Brunner‐La Rocca, Hans‐Peter, additional, and Brugts, Jasper J., additional

Published
2023
Full Text
View/download PDF

12. 1-Year Outcomes of Delayed Versus Immediate Intervention in Patients With Transient ST-Segment Elevation Myocardial Infarction

Author

Janssens, Gladys N., van der Hoeven, Nina W., Lemkes, Jorrit S., Everaars, Henk, van de Ven, Peter M., Marques, Koen M.J., Nap, Alexander, van Leeuwen, Maarten A.H., Appelman, Yolande, Knaapen, Paul, Verouden, Niels J.W., Allaart, Cornelis P., Brinckman, Stijn L., Saraber, Colette E., Plomp, Koos J., Timmer, Jorik R., Kedhi, Elvin, Hermanides, Renicus S., Meuwissen, Martijn, Schaap, Jeroen, van der Weerdt, Arno P., van Rossum, Albert C., Nijveldt, Robin, and van Royen, Niels

Published
2019
Full Text
View/download PDF

14. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Author

Hamid, Omid, Robert, Caroline, Daud, Adil, Hodi, F Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D, Hersey, Peter, Joseph, Richard W, Weber, Jeffrey S, Dronca, Roxana, Gangadhar, Tara C, Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M, Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Tumeh, Paul C, Chmielowski, Bartosz, Ebbinghaus, Scot W, Li, Xiaoyun Nicole, Kang, S Peter, and Ribas, Antoni

Subjects
Humans, Melanoma, Brain Neoplasms, Skin Neoplasms, Antineoplastic Agents, Antibodies, Monoclonal, Drug Administration Schedule, Dose-Response Relationship, Drug, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Antibodies, Monoclonal, Humanized, Programmed Cell Death 1 Receptor, Human Genome, Genetics, Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Cancer, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThe programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.MethodsWe administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not. Tumor responses were assessed every 12 weeks.ResultsA total of 135 patients with advanced melanoma were treated. Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade. The confirmed response rate across all dose cohorts, evaluated by central radiologic review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate observed in the cohort that received 10 mg per kilogram every 2 weeks (52%; 95% CI, 38 to 66). The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], respectively). Responses were durable in the majority of patients (median follow-up, 11 months among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of analysis in March 2013. The overall median progression-free survival among the 135 patients was longer than 7 months.ConclusionsIn patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. (Funded by Merck Sharp and Dohme; ClinicalTrials.gov number, NCT01295827.).

Published
2013

16. The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis.

Author

Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., and Brugts, Jasper J.

Subjects
HEART failure, PROGNOSIS, MORTALITY, DEATH rate, SCIENTIFIC observation, CONFIDENCE intervals
Abstract

Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all‐cause mortality and HF hospitalizations associated with new‐onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF. Methods and results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30‐day and 1‐year all‐cause mortality, as well as 1‐year HF hospitalization. Studies were pooled using random effects meta‐analysis, and mixed‐effects meta‐regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30‐day mortality rates did not reveal a significant distinction between hospital‐admitted patients, with rates of 10.13% for new‐onset HF and 8.11% for WHF (p = 0.10). However, the 1‐year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new‐onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend. Conclusions: Our meta‐analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE‐HF.

Author

Clephas, Pascal R. D., Malgie, Jishnu, Schaap, Jeroen, Koudstaal, Stefan, Emans, Mireille, Linssen, Gerard C. M., de Boer, Grytsje A., van Heerebeek, Loek, Borleffs, C. Jan Willem, Manintveld, Olivier C., van Empel, Vanessa, van Wijk, Sandra, van den Heuvel, Mieke, da Fonseca, Carlos, Damman, Kevin, van Ramshorst, Jan, van Kimmenade, Roland, van de Ven, Arjen R. T., Tio, René A., and van Veghel, Dennis

Subjects
HEART failure, DESIGN failures, DRUG therapy, VENTRICULAR ejection fraction, DIURETICS, DRUGS
Abstract

Aims: Current heart failure (HF) guidelines recommend to prescribe four drug classes in patients with HF with reduced ejection fraction (HFrEF). A clear challenge exists to adequately implement guideline‐directed medical therapy (GDMT) regarding the sequencing of drugs and timely reaching target dose. It is largely unknown how the paradigm shift from a serial and sequential approach for drug therapy to early parallel application of the four drug classes will be executed in daily clinical practice, as well as the reason clinicians may not adhere to new guidelines. We present the design and rationale for the real‐world TITRATE‐HF study, which aims to assess sequencing strategies for GDMT initiation, dose titration patterns (order and speed), intolerance for GDMT, barriers for implementation, and long‐term outcomes in patients with de novo, chronic, and worsening HF. Methods and results: A total of 4000 patients with HFrEF, HF with mildly reduced ejection fraction, and HF with improved ejection fraction will be enrolled in >40 Dutch centres with a follow‐up of at least 3 years. Data collection will include demographics, physical examination and vital parameters, electrocardiogram, laboratory measurements, echocardiogram, medication, and quality of life. Detailed information on titration steps will be collected for the four GDMT drug classes. Information will include date, primary reason for change, and potential intolerances. The primary clinical endpoints are HF‐related hospitalizations, HF‐related urgent visits with a need for intravenous diuretics, all‐cause mortality, and cardiovascular mortality. Conclusions: TITRATE‐HF is a real‐world multicentre longitudinal registry that will provide unique information on contemporary GDMT implementation, sequencing strategies (order and speed), and prognosis in de novo, worsening, and chronic HF patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized With COVID-19: A Multicenter Cohort Study

Author

Sluis, Wouter M., primary, Linschoten, Marijke, additional, Buijs, Julie E., additional, Biesbroek, J. Matthijs, additional, den Hertog, Heleen M., additional, Ribbers, Tessa, additional, Nieuwkamp, Dennis J., additional, van Houwelingen, Reinier C., additional, Dias, Andreas, additional, van Uden, Ingeborg W.M., additional, Kerklaan, Joost P., additional, Bienfait, H. Paul, additional, Vermeer, Sarah E., additional, de Jong, Sonja W., additional, Ali, Mariam, additional, Wermer, Marieke J.H., additional, de Graaf, Marieke T., additional, Brouwers, Paul J.A.M., additional, Asselbergs, Folkert W., additional, Kappelle, L. Jaap, additional, van der Worp, H. Bart, additional, Algra, Annemijn M., additional, Donders, Richard C.J.M., additional, Pruissen, D. Martijn O., additional, Kuijper, Aaf F.M., additional, van Ofwegen-Hanekamp, Clara E.E., additional, Hermanides, Rik S., additional, Haerkens-Arends, Hortence E., additional, Anthonio, Rutger L., additional, Emans, Mireille E., additional, Tio, René A., additional, ten Berg, Jur M., additional, Groenemeijer, Björn E., additional, Pisters, Ron, additional, van der Zee, P. Marc, additional, Siebelink, Hans-Marc J., additional, Verschure, Derk O., additional, Meijs, Matthijs F.L., additional, Schut, Astrid, additional, Tieleman, Robert G., additional, Hermans-van Ast, Wanda, additional, Schaap, Jeroen, additional, Jewbali, Lucia S., additional, Smits, Peter C., additional, van der Harst, Pim, additional, van Smeden, Maarten, additional, and van Gilst, Wiek H., additional

Published
2021
Full Text
View/download PDF

20. Coronary CT angiography for improved assessment of patients with acute chest pain and low-range positive high-sensitivity troponins: study protocol for a prospective, observational, multicentre study (COURSE trial)

Author

Arslan, Murat, primary, Schaap, Jeroen, additional, Van Gorsel, Bart, additional, Budde, Ricardo PJ, additional, Bekkers, Sebastiaan CAM, additional, Van Cauteren, Yvonne JM, additional, Damman, Peter, additional, Habets, Jesse, additional, Dubois, Eric A, additional, and Dedic, Admir, additional

Published
2021
Full Text
View/download PDF

21. Undetectable High-Sensitivity Troponin T as a Gatekeeper for Coronary Computed Tomography Angiography in Patients Suspected of Acute Coronary Syndrome

Author

Arslan, Murat, Schaap, Jeroen, Rood, Pleunie P.M., Nieman, Koen, Budde, Ricardo P.J., Van Dalen, Bas M., Attrach, Mohamed, Dubois, Eric A., Dedic, Admir, Arslan, Murat, Schaap, Jeroen, Rood, Pleunie P.M., Nieman, Koen, Budde, Ricardo P.J., Van Dalen, Bas M., Attrach, Mohamed, Dubois, Eric A., and Dedic, Admir

Abstract

Objectives: The aim of this study was to characterize the safety and efficiency of a strategy employing the limit of detection (LoD) of high-sensitivity troponin T (hs-TnT) as a gatekeeper for coronary computed tomography angiography (CCTA) in suspected acute coronary syndrome (ACS) patients in the emergency department (ED). Methods: We included suspected ACS patients who underwent CCTA and were evaluated with hs-TnT. Patients were categorized as below the LoD and at or above the LoD. The primary outcome was 30-day major adverse cardiac events (MACEs), defined as all-cause mortality, ACS, or coronary revascularization. Results: The study population consisted of 177 patients (mean age 55 ± 10 years, 50.3% women), and 16 (9.0%) patients reached the primary outcome. None of the patients died, while 13 had an adjudicated diagnosis of ACS, and 3 underwent elective coronary revascularization. There were 77 patients (44%) with an hs-TnT value below the LoD (MACEs; n = 1 [1.3%]) and 100 (56%) with at or above the LoD levels (MACEs; n = 15 [15%]). None of 67 patients with an hs-TnT value below the LoD and <50% stenosis on CCTA experienced MACEs. Out of the 10 patients with an hs-TnT value below the LoD and ≥50% stenosis on CCTA, 1 patient underwent elective percutaneous coronary revascularization. In patients with an hs-TnT value at or above the LoD, 74 patients had <50% stenosis on CCTA, and 2 patients (3%) were diagnosed with myocardial infarction without obstructive coronary artery disease confirmed on invasive angiography. Thirteen (50%) patients with an hs-TnT value at or above the LoD and ≥50% stenosis on CCTA experienced MACEs (11 ACS and 2 elective percutaneous coronary revascularizations). Conclusion: Our findings support that implementing the LoD of hs-TnT as a gatekeeper may reduce the need for CCTA in suspected ACS patients in the ED.

Published
2021

22. Coronary CT angiography for improved assessment of patients with acute chest pain and low-range positive high-sensitivity troponins:Study protocol for a prospective, observational, multicentre study (COURSE trial)

Author

Arslan, Murat, Schaap, Jeroen, Van Gorsel, Bart, Budde, Ricardo P.J., Bekkers, Sebastiaan C.A.M., Van Cauteren, Yvonne J.M., Damman, Peter, Habets, Jesse, Dubois, Eric A., Dedic, Admir, Arslan, Murat, Schaap, Jeroen, Van Gorsel, Bart, Budde, Ricardo P.J., Bekkers, Sebastiaan C.A.M., Van Cauteren, Yvonne J.M., Damman, Peter, Habets, Jesse, Dubois, Eric A., and Dedic, Admir

Abstract

Introduction Current evaluation of patients suspected of a non-ST-elevation acute coronary syndrome (NSTE-ACS) involves the use of algorithms that incorporate clinical information, electrocardiogram (ECG) and high-sensitivity cardiac troponins (hs-troponins). While primarily designed to rule out NSTE-ACS safely, these algorithms can also be used for rule in of NSTE-ACS in some patients. Still, in a substantial number of patients, these algorithms do not provide a conclusive work-up. These patients often present with an atypical clinical profile and low-range positive hs-troponin values without a characteristic rise or fall pattern. They represent a heterogeneous group of patients with various underlying conditions; only a fraction (30%-40%) will eventually be diagnosed with a myocardial infarction. Uncertainty exists about the optimal diagnostic strategy and their management depends on the clinical perspective of the treating physician ranging from direct discharge to admission for invasive coronary angiography. Coronary CT angiography (CCTA) is a non-invasive test that has been shown to be safe, fast and reliable in the evaluation of coronary artery disease. In this study, we will determine the usefulness of CCTA in patients with acute chest pain and low-range positive hs-troponin values. Methods and analysis A prospective, double-blind, observational, multicentre study conducted in the Netherlands. Patients aged 30-80 years presenting to the emergency department with acute chest pain and a suspicion of NSTE-ACS, a normal or non-diagnostic ECG and low-range positive hs-troponins will be scheduled to undergo CCTA. The primary outcome is the diagnostic accuracy of CCTA for the diagnosis of NSTE-ACS at discharge, in terms of sensitivity and negative predictive value. Ethics and dissemination This study was approved by the Medical Research Ethics Committee of Erasmus Medical Center in Rotterdam, the Netherlands (registration number MEC-2017-506). Written informed co

Published
2021

23. Diagnostic performance and clinical implications for enhancing a hybrid quantitative flow ratio-FFR revascularization decision-making strategy

Author

Researchgr. Cardiovasculaire Radiologie, Arts-assistenten Radiologie, Team Medisch, Circulatory Health, Global Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Peper, Joyce, van Hamersvelt, Robbert W, Rensing, Benno J W M, van Kuijk, Jan-Peter, Voskuil, Michiel, Berg, Jurriën M Ten, Schaap, Jeroen, Kelder, Johannes C, Grobbee, Diederick E, Leiner, Tim, Swaans, Martin J, Researchgr. Cardiovasculaire Radiologie, Arts-assistenten Radiologie, Team Medisch, Circulatory Health, Global Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Peper, Joyce, van Hamersvelt, Robbert W, Rensing, Benno J W M, van Kuijk, Jan-Peter, Voskuil, Michiel, Berg, Jurriën M Ten, Schaap, Jeroen, Kelder, Johannes C, Grobbee, Diederick E, Leiner, Tim, and Swaans, Martin J

Published
2021

24. Text-mining in electronic healthcare records can be used as efficient tool for screening and data-collection in cardiovascular trials: a multicenter validation study

Author

Global Health, Epi Methoden Team 4, JC onderzoeksprogramma Methodologie, Onderzoek Precision medicine, Cardiovasculaire Epi Team 5, Bioethics & Health Humanities, Circulatory Health, Team Medisch, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiologie, van Dijk, Wouter B, Fiolet, Aernoud T L, Schuit, Ewoud, Sammani, Arjan, Groenhof, T Katrien J, van der Graaf, Rieke, de Vries, Martine C, Alings, Marco, Schaap, Jeroen, Asselbergs, Folkert W, Grobbee, Diederick E, Groenwold, Rolf H H, Mosterd, Arend, Global Health, Epi Methoden Team 4, JC onderzoeksprogramma Methodologie, Onderzoek Precision medicine, Cardiovasculaire Epi Team 5, Bioethics & Health Humanities, Circulatory Health, Team Medisch, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiologie, van Dijk, Wouter B, Fiolet, Aernoud T L, Schuit, Ewoud, Sammani, Arjan, Groenhof, T Katrien J, van der Graaf, Rieke, de Vries, Martine C, Alings, Marco, Schaap, Jeroen, Asselbergs, Folkert W, Grobbee, Diederick E, Groenwold, Rolf H H, and Mosterd, Arend

Published
2021

26. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Author

Teerlink, John R., Diaz, Rafael, Felker, G. Michael, McMurray, John J.V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias‐Mendoza, Alexandra, Biering‐Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Cleland, John G.F., Corbalan, Ramon, Crespo‐Leiro, Maria G., Dahlström, Ulf, Echeverria Correa, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Cândida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Lund, Mayanna, Macdonald, Peter, Mareev, Vyacheslav, Momomura, Shin‐ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J. A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Abbasi, Siddique A., Varin, Claire, Malik, Fady I., Kurtz, Christopher E., Besada, Diego Alejandro, Majul, Claudio Rodolfo, Bruno, Marco Raul Litvak, Sassone, Sonia, Avaca, Horacio Alberto, Rasmussen, Mariela, Aiub, Jorge Roberto, Hominal, Miguel Angel, Perna, Eduardo, Duran, Ruben Omar Garcia, Schiavi, Lilia, Marquez, Lilia Luz Lobo, Vilamajo, Oscar Alberto Gomez, Mackinnon, Ignacio, Fuente, Ricardo Alfonso Leon, Montana, Oscar Romano, Novaretto, Leonardo, Guerrero, Rodolfo Andres Ahuad, Brasca, Daniela Garcia, Prado, Aldo, Garrido, Marcelo Alejandro, Luquez, Hugo, Martinez, Diego Felipe, Nicolosi, Liliana, Parody, Maria Leonor, Zaidman, Cesar, Berra, Fernando Colombo, Ibañez, Julio, Zapata, Gerardo, Caccavo, Alberto, Colque, Roberto, Diez, Mirta, Poy, Carlos, Salomone, Oscar Alejandro, Vogel, Daniel, Bordonava, Anselmo Paulino, Fernandez, Alberto, French, John, Atherton, John, Hamilton, Andrew, Begg, Alistair, Abhayaratna, Walter, Judkins, Christopher, De Pasquale, Carmine, McKenzie, Scott, Amerena, John, Szto, Gregory, Kearney, Leighton, Zimmet, Hendrik, Sverdlov, Aaron, Beltrame, John, Korczyk, Dariusz, Sindone, Andrew, Moertl, Deddo, Huber, Kurt, Huelsmann, Martin, Ablasser, Klemens, Ebner, Christian, Siostrzonek, Peter, Drexel, Heinz, Poelzl, Gerhard, Dujardin, Karl, Dupont, Matthias, Buysschaert, Ian, Lancellotti, Patrizio, Droogne, Walter, Chouchane, Iman, Silveira, Fabio, Rassi, Salvador, Reis, Gilmar, Filho, Pedro Pimentel, Simoes, Marcus Vinicius, Braga, Joao Carlos, Giorgeto, Flavio Eduardo, Ferraz, Almir, Jaeger, Cristiano Pederneiras, Saraiva, Jose Francisco, Tognon, Alexandre, Cardoso, Juliano, Greco, Oswaldo, Paiva, Maria Sanali, Paolino, Bruno, Filho, Otavio Coelho, Maia, Lilia Nigro, Silva, Rodrigo, Canesin, Manoel, Rossi, Paulo Roberto Ferreira, Fortes, Jose Augusto Ribas, Cerci, Rodrigo Julio, Manenti, Euler Roberto Fernandes, Leaes, Paulo Ernesto, Silva Neto, Luis Beck, Souza, Weimar Kunz Barroso, Bacal, Fernando, Chaves, Renato, Ramires, Felix, Vidotti, Maria Helena, Barros e Silva, Pedro Gabriel Melo, Piegas, Leopoldo Soares, Todorov, Georgi, Tzekova, Maria, Goudev, Assen, Mincheva, Valentina, Vasilev, Ivaylo, Tisheva‐ Gospodinova, Snezhanka, Petrov, Ivo, Postadzhiyan, Arman, Velikov, Chavdar, Dimov, Bojidar, Constance, Christian, Phaneuf, Denis‐Carl, Mielniczuk, Lisa, Pandey, A Shekhar, Senaratne, Manohara, Zieroth, Shelley, Savard, Daniel, Stewart, Robert, Huynh, Thao, Giannetti, Nadia, Moe, Gordon, Bourgeois, Ronald, Ezekowitz, Justin, Hartleib, Michael, Sussex, Bruce, Babapulle, Mohan, Chehayeb, Raja, Gaudet, Daniel, McKelvie, Robert, Nguyen, Viviane, Roth, Sherryn, Gupta, Milan, Pesant, Yves, Rupka, Dennis, Bhargava, Rakesh, Costa‐Vitali, Atilio, Proulx, Guy, Vega, Mario, Potthoff, Sergio, Cid, Maria Cristina Schnettler, Sepulveda, Alex Mauricio Villablanca, Zanetti, Fernando Tomas Lanas, Gajardo, Victor Areli Saavedra, Kindel, Carlos Conejeros, Jofre, Christian Paolo Pincetti, Segarra, Jorge Leonardo Cobos, Venegas, Manuel Eduardo Rodriguez, Hidalgo, Mario Yanez, Jalaf, Margarita Gertrudis Vejar, Li, Weimin, Zhang, Jinguo, Fu, Xin, Zhang, Xuelian, Li, Dongye, Wang, Zhifang, Qu, Yanling, Zheng, Zhe, Tang, Huifang, Yang, Ping, Zhang, Yuhui, Zheng, Yang, Mi, Yafei, Huang, He, Bu, Peili, Chen, Guoqin, Chen, Jiyan, Han, Yajun, Li, Zhangquan, Ma, Shumei, Yang, Xuming, Yuan, Zuyi, Dong, Yugang, Li, Zhaoping, Mahemuti, Ailiman, Niu, Wentang, Yang, Zhenyu, Zhang, Yuqing, Sun, Yuemin, Wu, Weiheng, Liu, Feng, Yan, Jing, Li, Yinjun, Wang, Yi, Zhang, Shouyan, Zhou, Changyong, Cui, Hanbin, Li, Jianjun, Li, Tianfa, Han, Qinghua, Wei, Yu, Correa, Luis Eduardo Echeverria, Mendoza, Jose Luis Accini, Jattin, Fernando Manzur, Osorio, Wilder Castaño, Luengas, Carlos Alberto, Arroyo, Julian Alonso Coronel, Corredor, Miguel Alfredo Moncada, Giraldo, Clara Ines Saldarriaga, Lopez, Rodrigo Botero, Salazar, Dora Ines Molina, Triana, Miguel Urina, Lopez, Luis Horacio Atehortua, Rojas, Pastor Olaya, Pelaez, Sebastian Velez, Pareja, Monica Lopez, Bonfanti, Alberto Cadena, Polasek, Rostislav, Monhart, Zdenek, Sochor, Karel, Motovska, Zuzana, Belohlavek, Jan, Busak, Ladislav, Krupicka, Jiri, Tyl, Petr, Jerabek, Ondrej, Podpera, Ivo, Skrobakova, Janka, Peterka, Karel, Spacek, Rudolf, Cech, Vladimir, Kellnerova, Ivana, Nechvatal, Libor, Pozdisek, Zbynek, Houra, Marek, Kryza, Radim, Machova, Vilma, Cepelak, Michal, Stepek, David, Zeman, Kamil, Klimsa, Zdenek, Koleckar, Pavel, Schee, Alexandr, Spinarova, Lenka, Coufal, Zdenek, Jeppesen, Jorgen, Vraa, Soren, Wiggers, Henrik, Nyvad, Ole, Nielsen, Tonny, Kaiser‐Nielsen, Peter, Videbaek, Lars, Galinier, Michel, Lefebvre, Jean‐Marie, Tartiere, Jean‐Michel, De Geeter, Guillaume, Roubille, Francois, Ricci, Jean Etienne, Salvat, Muriel, Gueffet, Jean‐Pierre, Decoulx, Eric, Berdague, Philippe, Jondeau, Guillaume, Ovize, Michel, Groote, Pascal De, Donal, Erwan, Isnard, Richard, Sabatier, Rémi, Trochu, Jean Noel, Damy, Thibaud, Georges, Jean‐Louis, Rosamel, Yann, Picard, François, Aboyans, Victor, Laperche, Thierry, Mitrovic, Veselin, Taggeselle, Jens, Störk, Stefan, Ebelt, Henning, Genth‐Zotz, Sabine, Rassaf, Tienush, Duengen, Hans‐Dirk, Mittag, Marcus, Menck, Niels, Zeymer, Uwe, Haehling, Stephan, Boehm, Michael, Frankenstein, Lutz, Killat, Holger, Bourhaial, Hakima, Beug, Daniel, Horacek, Thomas, Pfister, Roman, Sandri, Marcus, Westenfeld, Ralf, Kadel, Christoph, Karvounis, Haralambos, Patsilinakos, Sotirios, Mantas, Ioannis, Karavidas, Apostolos, Giamouzis, Grigorios, Tsioufis, Konstantinos, Naka, Katerina, Tziakas, Dimitrios, Parissis, John, Styliadis, Ioannis, Barbetseas, Ioannis, Manolis, Athanasios, Kochiadakis, George, Herczeg, Bela, Nagy, Laszlo, Nyolczas, Noemi, Toth, Kalman, Merkely, Bela, Laszlo, Zoltan, Mark, Laszlo, Szakal, Imre, Papp, Andras, Bezzegh, Katalin, Lakatos, Ferenc, Hajko, Erik, Papp, Aniko, Forster, Tamas, Lupkovics, Geza, Mohacsi, Attila, Salamon, Csaba, Aradi, Daniel, Andreka, Peter, Szasz, Gyula, Zilahi, Zsolt, Kazinczy, Rita, Margonato, Alberto, Agostoni, Piergiuseppe, Fucili, Alessandro, Piovaccari, Giancarlo, Senni, Michele, Carluccio, Erberto, Bilato, Claudio, Frigerio, Maria, Indolfi, Ciro, Sinagra, Gianfranco, Brunetti, Natale Daniele, Perna, Gianpiero, Pini, Daniela, Volterrani, Maurizio, Leonardi, Sergio, Mortara, Andrea, Friz, Hernan Emilio Francisco Polo, Rossini, Roberta, Tocchetti, Carlo Gabriele, Vincenzi, Antonella, Cavallini, Claudio, Floresta, Agata Marina, Zaca, Valerio, Giudici, Vittorio, Villani, Giovanni Quinto, Higashino, Yorihiko, Oishi, Shogo, Wada, Atsuyuki, Fukuzawa, Shigeru, Onoue, Kenji, Koike, Akihiro, Koizumi, Tomomi, Masuda, Seigo, Mitsuo, Kazuhisa, Takahashi, Natsuki, Takenaka, Takashi, Tanabe, Jun, Watanabe, Naoki, Yoshida, Takeshi, Amano, Tetsuya, Ishikawa, Masahiro, Kida, Keisuke, Kubota, Toru, Nakamura, Kentaro, Sakamoto, Tomohiro, Shimomura, Mitsuhiro, Yuge, Masaru, Doi, Masayuki, Domae, Hiroshi, Ebato, Mio, Fujii, Kenshi, Fujiwara, Wakaya, Gohara, Seiichiro, Hata, Yoshiki, Kanda, Junji, Kitaoka, Hiroaki, Matsumoto, Takashi, Michishita, Ichiro, Miura, Shinichiro, Miyazaki, Tetsuro, Nakamura, Akihiro, Ogawa, Tomohiro, Okumura, Takahiro, Okumura, Yasuo, Sakai, Tetsuo, Sato, Yukihito, Shimizu, Wataru, Sugino, Hiroshi, Suzuki, Masahiro, Takagi, Atsutoshi, Takaishi, Hiroshi, Tanaka, Takahiro, Terasaki, Toshiro, Tsujimoto, Mitsuru, Ueda, Yasunori, Ujino, Keiji, Usui, Makoto, Yamamoto, Mitsutaka, Yoshikawa, Masaki, Ando, Kenji, Asakura, Masanori, Asano, Hiroshi, Fujii, Shigeru, Hara, Hisao, Inomata, Takayuki, Isshiki, Takaaki, Kadokami, Toshiaki, Kai, Hisashi, Kasai, Toshio, Kawamitsu, Katsunori, Kawasaki, Tomohiro, Koga, Tokushi, Komiyama, Nobuyuki, Maejima, Yasuhiro, Manita, Mamoru, Miyamoto, Nobuhide, Node, Koichi, Numaguchi, Kotaro, Sakata, Yasushi, Serikawa, Takeshi, Takama, Noriaki, Tatebe, Shunsuke, Ueno, Hideki, Hidaka, Takayuki, Hiroi, Shitoshi, Iseki, Harukazu, Ito, Hiroshi, Kajinami, Kouji, Kawakami, Hideo, Momiyama, Yukihiko, Mori, Masuki, Morita, Yukiko, Okishige, Kaoru, Sakagami, Satoru, Takeishi, Yasuchika, Terasawa, Akihiro, Utsu, Noriaki, Badariene, Jolita, Celutkiene, Jelena, Slapikas, Rimvydas, Jarasuniene, Dalia, Castillo, Armando Garcia, De los Rios Ibarra, Manuel Odin, Lopez, Gabriel Arturo Ramos, Llamas, Edmundo Alfredo Bayram, Esperon, Guillermo Antonio Llamas, Vazquez, Eduardo Salcido, Gonzalez, Ricardo Garcia, Leon, Jose Luis Arenas, Gonzalez, Salvador Leon, Mendoza, Maria Alexandra Arias, Rodriguez, Alicia Contreras, Machado, Gustavo Francisco Mendez, Salazar, Melchor Alpizar, Ruiz, Alberto Esteban Bazzoni, Flores, Ana Maria De Leon, Carrasco, Jose Alfredo Pagola, Araiza, Raul Reyes, Römer, Tjeerd, Remmen, Johannes, Van Eck, Jacob, Elvan, Arif, Smilde, Tom, Voors, Adriaan, Wal, Ruud, Schaap, Jeroen, Sluis, Aize, Linssen, Gerardus, Magro, Michael, Willems, Frank, Hal, John, Zwaan, Coenraad, Beelen, Driek, Boswijk, Dirk, Hermans, Walter, Van Kesteren, Henricus, Scott, Russell, Hart, Hamish, Lund, Marianne, Szczasny, Marcin, Blicharski, Tomasz, Kafara, Mariusz, Stankiewicz, Anna, Skonieczny, Grzegorz, Zabowka, Maciej, Kania, Grzegorz, Kopaczewski, Jerzy, Pawlowicz, Lidia, Spyra, Janusz, Wlodarczyk, Aleksander, Sciborski, Ryszard, Balsam, Pawel, Drozdz, Jaroslaw, Sobkowicz, Bozena, Konieczynska, Malgorzata, Lelonek, Malgorzata, Bednarkiewicz, Zbigniew, Trebacz, Jaroslaw, Jankowski, Piotr, Sidor, Mateusz, Berkowski, Piotr, Chmielak, Zbigniew, Lenartowska, Lucyna, Nessler, Jadwiga, Straburzynska‐Migaj, Ewa, Kalarus, Zbigniew, Kowalski, Robert, Kalecinska‐Krystkiewicz, Ewa, Gola, Zbigniew, Pijanowski, Zbigniew, Wozakowska‐Kaplon, Beata, Cymerman, Krzysztof, Rynkiewicz, Andrzej, Miekus, Pawel, Monteiro, Pedro, Sarmento, Pedro Morais, Almeida, Filipa, Duarte, Tatiana, Fonseca, Candida, Oliveira, Luis, Santos, Luis, Brito, Dulce, Stanciulescu, Gabriela, Spiridon, Marilena Renata, Militaru, Constantin, Podoleanu, Cristian Gheorghe, Zdrenghea, Dumitru, Popescu, Mircea Ioachim, Macarie, Cezar‐Eugen, Giuca, Alina, Mitu, Florin, Voicu, Olga‐Cristina, Dorobantu, Maria, Lighezan, Daniel, Stamate, Sorin, Bykov, Alexander, Kobalava, Zhanna, Zrazhevskiy, Konstantin, Semenova, Irina, Vishnevsky, Alexander, Shutemova, Elena, Tereschenko, Sergey, Shvarts, Yury, Barbarash, Olga, Lukyanov, Yury, Voevoda, Mikhail, Dovgolis, Svetlana, Dronov, Dmitry, Goloshchekin, Boris, Sitnikova, Maria, Ezhov, Marat, Tarasov, Nikolay, Kotelnikov, Mikhail, Kostenko, Viktor, Solovev, Oleg, Goncharov, Ivan, Myasnikov, Roman, Rafalskiy, Vladimir, Ryabov, Vyacheslav, Kosmacheva, Elena, Motylev, Igor, Nosov, Vladimir, Osipova, Irina, Salukhov, Vladimir, Belenkiy, Dmitriy, Bolshakova, Olga, Pimenov, Leonid, Shilkina, Nataliya, Kulibaba, Elena, Repin, Alexey, Timofeev, Alexander, Mitrokhin, Vladislav, Sherenkov, Alexander, Arbolishvili, Georgy, Antalik, Lubomir, Dzupina, Andrej, Fulop, Peter, Majercak, Ivan, Gonsorcik, Jozef, Vinanska, Daniela, Lenner, Egon, Lukacova, Jana, Margoczy, Roman, Smik, Rudolf, Stevlik, Jan, Uhliar, Rudolf, Burgess, Lesley, Badat, Aysha, Klug, Eric, Van Zyl, Louis, Abelson, Mark, Moodley, Rajendran, Tsabedze, Nqoba, Fourie, Nyda, Bonet, Luis Almenar, Prado, Jose Maria Arizon, Oliveira Soares, Manue Martinez‐Selles D, Villota, Julio Eduardo Nuñez, Leiro, Maria Generosa Crespo, Juanatey, Jose Ramon Gonzalez, Figal, Domingo Andres Pascual, Palomas, Juan Luis Bonilla, Perez, Sonia Mirabet, Jimenez, Juan Francisco Delgado, Padron, Antonio Lara, Diaz, Victor Alfonso Jimenez, Cubero, Javier Segovia, Paya, Vicente Eduardo Climent, Mayoral, Alejandro Recio, Fuente Galan, Luis, Doblas, Juan Jose Gomez, Freire, Ramon Bover, Peiro, Maria Teresa Blasco, Molina, Beatriz Diaz, Martinez, Laura Jordan, Vilchez, Francisco Gonzalez, Boman, Kurt, Karlstrom, Patric, Berglund, Stefan, Szabo, Barna, Peterson, Magnus, Wodlin, Peter, Lindholm, Carl‐Johan, Moccetti, Tiziano, Mueller, Christian, Suter, Thomas, Hullin, Roger, Meyer, Philippe, Noll, Georg, Yigit, Zerrin, Turgut, Okan Onur, Bekar, Lutfu, Sahin, Tayfun, Koldas, Zehra Lale, Celik, Ahmet, Cavusoglu, Yuksel, Demir, Mesut, Onrat, Ersel, Duzenli, Mehmet, Cosansu, Kahraman, Muderrisoglu, Ibrahim Haldun, Tuncer, Mustafa, Badak, Ozer, Nalbantgil, Sanem, Kirma, Cevat, Okuyan, Ertugrul, Guray, Umit, Prokhorov, Oleksandr, Karpenko, Oleksandr, Vakaliuk, Igor, Yagensky, Andriy, Kracz, Igor, Stanislavchuk, Mykola, Kulynych, Oleksii, Rishko, Mykola, Stets, Roman, Tseluyko, Vira, Mishchenko, Larysa, Rudenko, Leonid, Rudyk, Iurii, Alieksieieva, Liudmyla, Korzh, Oleksii, Mostovoy, Yuriy, Parkhomenko, Oleksandr, Rasputina, Lesya, Voronkov, Leonid, Lymar, Yurii, Vasilyeva, Larysa, Keeling, Philip, Barr, Craig, Wong, Kenneth, Price, Dallas, Skaria, Binoy, Clark, Andrew, Chandrasekaran, Badrinathan, Trevelyan, Jasper, Gordon, Brian, Donnelly, Patrick, Glover, Jason, Ryding, Alisdair, Weir, Robin, Lang, Chim, Roy, Debashis, Adhya, Shaumik, Clifford, Piers, Ludman, Andrew, Kalra, Paul, Lynch, Mary, Mahmood, Shahid, Al Mohammad, Abdallah, Asubiaro, Joshua, Elmahi, Einas, Muthumala, Amal, Taylor, Justin, Gupta, Dinesh, Nadar, Venkatesh, Henderson, David, Zolty, Ronald, Sauer, Andrew, Adams, Kirkwood, Chandra, Lokesh, Jaffrani, Naseem, Grewal, Gurinder, Mancini, Donna, McLean, Dalton, Vasallo, Javier, Gottlieb, Stephen, Joseph, Susan, Barua, Rajat, Gorodeski, Eiran, Mouhaffel, Asad, Chung, Eugene, Desai, Pratik, Portnay, Edward, Rama, Bhola, Shandling, Adrian, Stahl, Llyod, Heilman, Karl, Jacob, Binu, Londono, Juan, Almousalli, Omar, Ashcom, Thomas, Bauerlein, Eugene Joseph, Koo, Charles, McGrew, Frank, Rajagopalan, Navin, Robinson, Shawn, Schultz, David, Starling, Randall, Ambardekar, Amrut, Bhagwat, Ravi, Boehmer, John, Bouza, Manuel, Farris, Neil, Feitell, Scott, Ganji, Jagadeesh, Geltman, Edward, Javier, Julian, Morrow, John Andrew, Pianko, Leonard, Smart, Frank, Adler, Alexander, Brinkley, Douglas, Cardona, Jose, Coletti, Andrew, Harris, John, Hunter, Vernon, Krantz, Mori, Lang, Christopher, Lovell, Charles, Murray, David, Pillutla, Priya, Shah, Amit, Bogaev, Roberta, Dauber, Ira, Franchi, Francesco, Fremont, Richard, Hart, Terence, Hattler, Brack, Janik, Matthew, Khalife, Wissam, Malhotra, Sanjay, Mamdani, Shafiq, Nelson, William, Orgera, Marisa, Ortiz, Aurelio, Rahko, Peter, Rennyson, Stephen, Shin, Jooyoung, Tsao, Lana, Uretsky, Barry, Wahid, Faisal, Wilkett, Matt, Amanullah, Aman, Baker, Mathue, Berk, Martin, Boccalandro, Fernando, Cruz, Kimberly, Doyle, Timothy, Gianfagna, Robert, Jones, Alonzo, King, Anthony, Lepor, Norman, Martinez‐Castrillon, Melvin, Pham, Michael, Radin, Michael, Radojevic, Joseph, Ramanathan, Kodangudi, Schmalfuss, Carsten, Schnitzler, Robert, Shah, Keyur, Takata, Theodore, Bertolet, Barry, Bostick, Brian, Civitello, Andrew, Collins, John, Dib, Nabil, Fang, James, Gilmore, Richard, Gray, Wayne, Grazette, Luanda, Haddad, Tariq, Hearne, Steven, Janmohamed, Munir, Katz, Richard, Kazemi, Navid, Llerena, Sara, Lohr, Nicole, Marzouka, George, Mignone, John, Ooi, Henry, Paszczuk, Anna, Pickett, Christopher, Sampognaro, Gregory, Sawyer, Douglas, Shayani, Steven, Treasure, Charles, Vaz, Garth, Vijay, Nampalli, Williams, Celeste, Yeoman, Gary, Zhang, Lily, Aaronson, Keith, Abo‐Auda, Wael, Alharethi, Rami, Anderson, William, Ariani, Mehrdad, Banerji, Sourin, Baweja, Paramdeep, Carson, Peter, Eberly, Arthur, Elliott, James, Fernando, Ronald, Fisher, Daniel, Forman, Steven, Gabriel, George, Gogia, Harinder, Hametz, Craig, Houston, Brian, Ibrahim, Hassan, Jadbabaie, Farid, Kassiotis, Christos, Krishnamoorthy, Arun, Kwan, Michael, Lupovitch, Steven, Macias, Leonardo, Malik, Adnan, Martinez, Luis, Miyamoto, Michael, Mody, Freny, Patel, Devesh, Peart, Brenda, Pisani, Barbara, Ramos, Mark, Rivero, Mariel, Shah, Anil, Sharma, Mukesh, Sichrovsky, Tina, Simon, Marc, Singh, Deovrat, Tallet, Julio, Vaccari, Christopher, Villoch, Mario, Wheeler, Matthew, Yousuf, Kabir, Abadier, Rafik, Abdullah, Shuaib, Arora, Raveen, Aslam, Shamaila, Buynak, Robert, Chang, David, Contreras, Johanna, Halpern, Stephen, Handel, Franklin, Heitner, John, Herzog, William, Jackson, Bruce, Kao, John, Kondo, Nicholas, Koren, Michael, LeWinter, Martin, Martindale, Jeffrey, Martinez‐Arraras, Joaquin, Olsen, Stephanie, Piatek, Marek, Ranadive, Nandkishore, Randall, William, Rao, Sunder, Rawitscher, David, Rider, James, Sokos, George, Strader, J Russell, Sulemanjee, Nasir, Tahirkheli, Naeem, Trichon, Benjamin, Vanhecke, Thomas, Whellan, David, Abuannadi, Mohammad, Aggarwala, Gaurav, Ahmad, Saad, Artis, Andre, Cheirif, Jorge, Cotarlan, Vladimir, Cox, Jeremy, Eaton, Charles, Florea, Viorel, Frank, Theodore, Friedman, Keith, Ganeshram, Vedampattu, Gass, Alan, Gemignani, Anthony, Hasni, Syed, Hedgepeth, Chester, Itchhaporia, Dipti, Kaluski, Edo, Karim, Amin, Kono, Alan, Lader, Ellis, Lakshminarayanan, Batlagundu, Lewis, Neil, Malhotra, Vinay, Mayer, Nolan, Mohapatra, Robert, Nair, Nandini, O'Brien, Terrence, Pauwaa, Sunil, Rowan, Christopher, Saxena, Sanjeev, Seto, Arnold, Shah, Nishant, Singh, Pradeep, Skopicki, Hal, Stoddard, Marcus, and Sweitzer, Nancy

Subjects
R1
Abstract

Aims:\ud The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials.\ud \ud Methods and Results:\ud Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure

Published
2020

29. Diurnal modulation of pacemaker potentials and calcium current in the mammalian circadian clock

Author

Pennartz, Cyriel M. A., de Jeu, Marcel T. G., Bos, Nico P. A., Schaap, Jeroen, and Geurtsen, Alwin M. S.

Subjects
Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): Cyriel M. A. Pennartz (corresponding author); Marcel T. G. de Jeu; Nico P. A. Bos; Jeroen Schaap; Alwin M. S. Geurtsen It has long been known that neurons in [...]

Published
2002
Full Text
View/download PDF

32. TEXT-MINING IN ELECTRONIC HEALTHCARE RECORDS FOR EFFICIENT RECRUITMENT AND DATA-COLLECTION IN CARDIOVASCULAR TRIALS: A MULTICENTER VALIDATION STUDY

Author

Dijk, Wouter Van, primary, Fiolet, Aernoud, additional, Schuit, Ewoud, additional, Sammani, Arjan, additional, Groenhof, Katrien, additional, van der Graaf, Rieke, additional, de Vries, Martine, additional, Alings, Marco, additional, Schaap, Jeroen, additional, Asselbergs, Folkert, additional, Grobbee, Diederick, additional, Groenwold, Rolf, additional, and Mosterd, Arend, additional

Published
2020
Full Text
View/download PDF

34. IMMEDIATE VERSUS DELAYED REVASCULARIZATION IN PATIENTS WITH TRANSIENT ST-ELEVATION MYOCARDIAL INFARCTION: 1-YEAR FOLLOW-UP OF THE RANDOMIZED CLINICAL TRANSIENT TRIAL

Author

Janssens, Gladys, primary, Lemkes, Jorrit, additional, van der Hoeven, Nina, additional, van de Ven, Peter, additional, Marques, Koen, additional, Nap, Alexander, additional, Van Leeuwen, Maarten, additional, Appelman, Yolande, additional, Knaapen, Paul, additional, Verouden, Cornelius, additional, Allaart, Cornelis, additional, Brinckman, Stijn, additional, Saraber, Colette, additional, Plomp, Koos, additional, Timmer, Jorik, additional, Kedhi, Elvin, additional, Hermanides, Rik, additional, Meuwissen, Martijn, additional, Schaap, Jeroen, additional, Van Der Weerdt, Arno, additional, van Rossum, Albert, additional, Nijveldt, Robin, additional, and Van Royen, Niels, additional

Published
2019
Full Text
View/download PDF

35. Blood-Based Biomarkers of Quinpirole Pharmacology: Cluster-Based PK/PD and Metabolomics to Unravel the Underlying Dynamics in Rat Plasma and Brain

Author

van den Brink, Willem J., primary, Hartman, Robin, additional, van den Berg, Dirk-Jan, additional, Flik, Gunnar, additional, Gonzalez-Amoros, Belén, additional, Koopman, Nanda, additional, Elassais-Schaap, Jeroen, additional, van der Graaf, Piet Hein, additional, Hankemeier, Thomas, additional, and de Lange, Elizabeth C.M., additional

Published
2019
Full Text
View/download PDF

36. Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Author

Joseph, Richard W., primary, Elassaiss-Schaap, Jeroen, additional, Kefford, Richard, additional, Hwu, Wen-Jen, additional, Wolchok, Jedd D., additional, Joshua, Anthony M., additional, Ribas, Antoni, additional, Hodi, F. Stephen, additional, Hamid, Omid, additional, Robert, Caroline, additional, Daud, Adil, additional, Dronca, Roxana, additional, Hersey, Peter, additional, Weber, Jeffrey S., additional, Patnaik, Amita, additional, de Alwis, Dinesh P., additional, Perrone, Andrea, additional, Zhang, Jin, additional, Kang, S. Peter, additional, Ebbinghaus, Scot, additional, Anderson, Keaven M., additional, and Gangadhar, Tara C., additional

Published
2018
Full Text
View/download PDF

37. Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial

Author

Lemkes, Jorrit S, primary, Janssens, Gladys N, additional, van der Hoeven, Nina W, additional, van de Ven, Peter M, additional, Marques, Koen M J, additional, Nap, Alexander, additional, van Leeuwen, Maarten A H, additional, Appelman, Yolande E A, additional, Knaapen, Paul, additional, Verouden, Niels J W, additional, Allaart, Cornelis P, additional, Brinckman, Stijn L, additional, Saraber, Colette E, additional, Plomp, Koos J, additional, Timmer, Jorik R, additional, Kedhi, Elvin, additional, Hermanides, Renicus S, additional, Meuwissen, Martijn, additional, Schaap, Jeroen, additional, van der Weerdt, Arno P, additional, van Rossum, Albert C, additional, Nijveldt, Robin, additional, and van Royen, Niels, additional

Published
2018
Full Text
View/download PDF

38. Crowdsourced Asparagus Urinary Odor Population Kinetics

Author

Ramamoorthy, Anuradha, primary, Sadler, Brian M., additional, van Hasselt, J.G. Coen, additional, Elassaiss-Schaap, Jeroen, additional, Kasichayanula, Sreeneeranj, additional, Edwards, Alena Y., additional, van der Graaf, Piet H., additional, Zhang, Lei, additional, and Wagner, John A., additional

Published
2017
Full Text
View/download PDF

39. Blood‐Based Biomarkers of Quinpirole Pharmacology: Cluster‐Based PK/PD and Metabolomics to Unravel the Underlying Dynamics in Rat Plasma and Brain.

Author

Brink, Willem J., Hartman, Robin, Berg, Dirk‐Jan, Flik, Gunnar, Gonzalez‐Amoros, Belén, Koopman, Nanda, Elassais‐Schaap, Jeroen, Graaf, Piet Hein, Hankemeier, Thomas, and Lange, Elizabeth C.M.

Subjects
PSYCHIATRIC drugs, PHARMACOLOGY, METABOLOMICS, LABORATORY rats, BLOOD plasma, BRAIN physiology
Abstract

A key challenge in the development of central nervous system drugs is the availability of drug target specific blood‐based biomarkers. As a new approach, we applied cluster‐based pharmacokinetic/pharmacodynamic (PK/PD) analysis in brain extracellular fluid (brainECF) and plasma simultaneously after 0, 0.17, and 0.86 mg/kg of the dopamine D2/3 agonist quinpirole (QP) in rats. We measured 76 biogenic amines in plasma and brainECF after single and 8‐day administration, to be analyzed by cluster‐based PK/PD analysis. Multiple concentration‐effect relations were observed with potencies ranging from 0.001–383 nM. Many biomarker responses seem to distribute over the blood‐brain barrier (BBB). Effects were observed for dopamine and glutamate signaling in brainECF, and branched‐chain amino acid metabolism and immune signaling in plasma. Altogether, we showed for the first time how cluster‐based PK/PD could describe a systems‐response across plasma and brain, thereby identifying potential blood‐based biomarkers. This concept is envisioned to provide an important connection between drug discovery and early drug development. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial.

Author

Lemkes, Jorrit S, Janssens, Gladys N, Hoeven, Nina W van der, Ven, Peter M van de, Marques, Koen M J, Nap, Alexander, Leeuwen, Maarten A H van, Appelman, Yolande E A, Knaapen, Paul, Verouden, Niels J W, Allaart, Cornelis P, Brinckman, Stijn L, Saraber, Colette E, Plomp, Koos J, Timmer, Jorik R, Kedhi, Elvin, Hermanides, Renicus S, Meuwissen, Martijn, Schaap, Jeroen, and Weerdt, Arno P van der

Abstract

Aims Patients with acute coronary syndrome who present initially with ST-elevation on the electrocardiogram but, subsequently, show complete normalization of the ST-segment and relief of symptoms before reperfusion therapy are referred to as transient ST-segment elevation myocardial infarction (STEMI) and pose a therapeutic challenge. It is unclear what the optimal timing of revascularization is for these patients and whether they should be treated with a STEMI-like or a non-ST-segment elevation myocardial infarction (NSTEMI)-like invasive approach. The aim of the study is to determine the effect of an immediate vs. a delayed invasive strategy on infarct size measured by cardiac magnetic resonance imaging (CMR). Methods and results In a randomized clinical trial, 142 patients with transient STEMI with symptoms of any duration were randomized to an immediate (STEMI-like) [0.3 h; interquartile range (IQR) 0.2–0.7 h] or a delayed (NSTEMI-like) invasive strategy (22.7 h; IQR 18.2–27.3 h). Infarct size as percentage of the left ventricular myocardial mass measured by CMR at day four was generally small and not different between the immediate and the delayed invasive group (1.3%; IQR 0.0–3.5% vs. 1.5% IQR 0.0–4.1%, P  = 0.48). By intention to treat, there was no difference in major adverse cardiac events (MACE), defined as death, reinfarction, or target vessel revascularization at 30 days (2.9% vs. 2.8%, P  =   1.00). However, four additional patients (5.6%) in the delayed invasive strategy required urgent intervention due to signs and symptoms of reinfarction while awaiting angiography. Conclusion Overall, infarct size in transient STEMI is small and is not influenced by an immediate or delayed invasive strategy. In addition, short-term MACE was low and not different between the treatment groups. View large Download slide View large Download slide [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

41. Coronary CT Angiography for Suspected ACS in the Era of High-Sensitivity Troponins

Author

Dedic, Admir, primary, Lubbers, Marisa M., additional, Schaap, Jeroen, additional, Lammers, Jeronymus, additional, Lamfers, Evert J., additional, Rensing, Benno J., additional, Braam, Richard L., additional, Nathoe, Hendrik M., additional, Post, Johannes C., additional, Nielen, Tim, additional, Beelen, Driek, additional, le Cocq d’Armandville, Marie-Claire, additional, Rood, Pleunie P.M., additional, Schultz, Carl J., additional, Moelker, Adriaan, additional, Ouhlous, Mohamed, additional, Boersma, Eric, additional, and Nieman, Koen, additional

Published
2016
Full Text
View/download PDF

43. Crowdsourced Asparagus Urinary Odor Population Kinetics.

Author

Ramamoorthy, Anuradha, Sadler, Brian M., van Hasselt, J. G. Coen, Elassaiss‐Schaap, Jeroen, Kasichayanula, Sreeneeranj, Edwards, Alena Y., van der Graaf, Piet H., Zhang, Lei, and Wagner, John A.

Subjects
CLINICAL pharmacology, ASPARAGUS, ODORS, CLINICAL trials, DIMETHYL sulfone, PHYSIOLOGY
Abstract

The consumption of asparagus is associated with the production of malodorous urine with considerable interindividual variability (IIV). To characterize the urinary odor kinetics after consumption of asparagus spears, we conducted a study with consenting attendees from two American Society for Clinical Pharmacology and Therapeutics (ASCPT) meetings. Subjects were randomized to eat a specific number of asparagus spears, and then asked to report their urinary odor perception. Eighty‐seven subjects were included in the final analysis. A mixed effect proportional odds model was developed that adequately characterized the dose‐response relationship. We estimated the half‐life of the asparagus effect on malodorous urine to be 4.7 hours (relative standard error (RSE) = 13.2%), and identified a dose‐response slope term with good precision (24.3%). Age was found as the predictor of IIV in slope estimates. This study design and tools can be used as a demonstration “crowdsourcing” project for studying population kinetics in organizational and educational settings. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

46. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Author

Patnaik, Amita, primary, Kang, S. Peter, additional, Rasco, Drew, additional, Papadopoulos, Kyriakos P., additional, Elassaiss-Schaap, Jeroen, additional, Beeram, Muralidhar, additional, Drengler, Ronald, additional, Chen, Cong, additional, Smith, Lon, additional, Espino, Guillermo, additional, Gergich, Kevin, additional, Delgado, Liliana, additional, Daud, Adil, additional, Lindia, Jill A., additional, Li, Xiaoyun Nicole, additional, Pierce, Robert H., additional, Yearley, Jennifer H., additional, Wu, Dianna, additional, Laterza, Omar, additional, Lehnert, Manfred, additional, Iannone, Robert, additional, and Tolcher, Anthony W., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results